Paper39745587
Eculizumab as rescue therapy for relapse of myasthenia gravis after immune-checkpoint inhibitors: a case report.
Rigamonti A and 3 others. Neurol Sci, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Eculizumab as rescue therapy for relapse of myasthenia gravis after immune-checkpoint inhibitors: a case report. Papers, record 39745587. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39745587
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Eculizumab as rescue therapy for relapse of myasthenia gravis after immune-checkpoint inhibitors: a case report.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References17
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18642357 | Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. | Muscle Nerve | 2008 | https://conductscience.org/library/papers/18642357 | PubMed |
| 2 | 38108913 | Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors. | Neurol Sci | 2024 | https://conductscience.org/library/papers/38108913 | PubMed |
| 3 | 37389303 | Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. | Brain Commun | 2023 | https://conductscience.org/library/papers/37389303 | PubMed |
| 4 | 29066163 | Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. | Lancet Neurol | 2017 | https://conductscience.org/library/papers/29066163 | PubMed |
| 5 | 20439845 | The MG Composite: A valid and reliable outcome measure for myasthenia gravis. | Neurology | 2010 | https://conductscience.org/library/papers/20439845 | PubMed |
| 6 | 36924454 | Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis. | Ann Clin Transl Neurol | 2023 | https://conductscience.org/library/papers/36924454 | PubMed |
| 7 | 34378270 | Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. | Oncologist | 2021 | https://conductscience.org/library/papers/34378270 | PubMed |
| 8 | 31092901 | Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. | Nat Rev Clin Oncol | 2019 | https://conductscience.org/library/papers/31092901 | PubMed |
| 9 | 30078154 | Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors. | Curr Neurol Neurosci Rep | 2018 | https://conductscience.org/library/papers/30078154 | PubMed |
| 10 | 36614930 | Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series. | J Clin Med | 2022 | https://conductscience.org/library/papers/36614930 | PubMed |
| 11 | 38205840 | Novel uses of complement inhibitors in myasthenia gravis-Two case reports. | Muscle Nerve | 2024 | https://conductscience.org/library/papers/38205840 | PubMed |
| 12 | 22006686 | MG-ADL: still a relevant outcome measure. | Muscle Nerve | 2011 | https://conductscience.org/library/papers/22006686 | PubMed |
| 13 | 37884388 | Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade. | Neurol Neuroimmunol Neuroinflamm | 2024 | https://conductscience.org/library/papers/37884388 | PubMed |
| 14 | 28821685 | Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. | Neurology | 2017 | https://conductscience.org/library/papers/28821685 | PubMed |
| 15 | 10921745 | Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. | Ann Thorac Surg | 2000 | https://conductscience.org/library/papers/10921745 | PubMed |
| 16 | 35438755 | Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis. | JAMA Netw Open | 2022 | https://conductscience.org/library/papers/35438755 | PubMed |
| 17 | 32765397 | Immune Checkpoint Inhibitor-Induced Myasthenia Gravis. | Front Neurol | 2020 | https://conductscience.org/library/papers/32765397 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42840483 | Immune checkpoint inhibitor-induced myocarditis with myositis and/or myasthenia gravis overlap syndrome: A case series. | Exp Ther Med | 2026 | https://conductscience.org/library/papers/42840483 | PubMed |
| 41857416 | Italian recommendations for the diagnosis and treatment of myasthenia gravis. | Neurol Sci | 2026 | https://conductscience.org/library/papers/41857416 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39745587
GET https://conductscience.org/api/papers/v1/39745587/authors